Can a new drug combo make pancreatic cancer surgery more effective?

NCT ID NCT07806110

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This phase II trial tests whether adding an experimental drug called SHR-1701 to a standard chemotherapy regimen can improve outcomes for people with pancreatic cancer that is resectable or borderline resectable. Participants receive the combination before surgery, with the goal of shrinking tumors to allow for complete removal. The main measure of success is the rate of R0 resection, meaning surgery with clear margins, which is linked to better long-term survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SHR-1701 combined with liposomal irinotecan, nab-paclitaxel, and gemcitabine
What this could lead to
If successful, this approach could shrink pancreatic tumors before surgery, making complete removal more likely and potentially extending survival for patients with resectable or borderline resectable disease.
What could go wrong
This is a phase II trial with a modest number of participants, so results may not hold up in larger studies. The drug combination carries risks of side effects, and not all patients will benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 62 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years, male or female; 2. Resectable or borderline resectable pancreatic cancer 3. No prior anti-tumor therapy (including radiotherapy, ablation, chemotherapy, targeted therapy, immunotherapy, etc.) or investigational drug treatment 4. At least one measurable lesion as a target lesion according to RECIST v1.1 criteria 5. ECOG performance status: 0-1 6. Expected survival time ≥3 months 7. Adequate major organ function Exclusion Criteria: 1. Patients with pancreatic tumors originating from non-pancreatic ductal epithelium, including pancreatic neuroendocrine carcinoma, pancreatic acinar cell carcinoma, pancreatoblastoma, and solid-pseudopapillary neoplasm 2. Known central nervous system (CNS) metastases 3. Severe gastrointestinal dysfunction (e.g., GI bleeding, obstruction, Grade \>2 inflammation, or Grade \> 1 diarrhea); 4. Symptomatic ascites requiring paracentesis or drainage, or patients who have received ascites drainage within the past 3 months (except for those with asymptomatic, controllable minimal ascites detected solely on imaging); 5. Current interstitial lung disease (ILD) or pneumonitis; 6. Known peripheral neuropathy (CTCAE Grade ≥3); 7. Coagulation dysfunction, bleeding tendency, or current thrombolytic or full-dose anticoagulant therapy. 8. Uncontrolled clinical cardiovascular symptoms or diseases; 9. Malignancy other than pancreatic cancer within 5 years prior to randomization, with the exception of adequately treated cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin; 10. Known hypersensitivity to liposomal irinotecan, other liposomal formulations, gemcitabine, nab-paclitaxel, retlirafusp alfa injection, or any component of these products; 11. Known Acquired Immunodeficiency Syndrome (AIDS), positive HIV antibody test, or active syphilis infection; 12. History of neurological or psychiatric disorders, including epilepsy or dementia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreas ductal adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Hospital of Jilin University

    Changchun, Jilin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.